Search Results
Jun 30, 2026, 09:00 ET A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
with potential targets and indications expanding beyond oncology.The update arrives as its clinical programs advance: GTB-3650 (Phase 1, CD33-expressing blood cancers) and GTB-5550 (Phase 1, B7-H3-expressing solid tumors), with the first GTB-5550 patient dosed in May 2026.Other
More news about: USA News Group
Jun 30, 2026, 09:00 ET Sonar Launches Sonar Vortex and SonarQube Remediation Agent to Improve Agentic Effectiveness
write a single line of code. This includes the same organizational standards, quality profiles, and security rules that govern projects throughout CI/CD. It then verifies agent output in real time, inside the inner loop, catching security, reliability, and maintainability issues before any PR exists.
More news about: Sonar
Jun 30, 2026, 07:15 ET ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
clinicaltrials.gov (NCT04970901).About ZYNLONTA®ZYNLONTA® is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The
More news about: ADC Therapeutics SA
Jun 30, 2026, 07:00 ET CD&R Foundation Awards Grants to Five New York City Non-Profit Organizations Expanding Economic Opportunity
2026 /PRNewswire/ -- CD&R (or the "Firm") today announced that the CD&R Foundation (the "Foundation") has made grants totaling $4.5 million to five non-profit organizations in New York City, to be dispersed over the next four years. These organizations, identified as CD&R's Talent Solution Partners
More news about: CD&R
Jun 29, 2026, 23:07 ET Gartner identifica quatro ameaças críticas que exigem melhorias urgentes por parte dos líderes em segurança cibernética
devem trabalhar no sentido de criar registros confiáveis de componentes, fortalecer seus pipelines de integração contínua / desenvolvimento contínuo (CI/CD) e desenvolver capacidades robustas de detecção e resposta a anomalias operacionais."As equipes de segurança cibernética devem criar inventários
More news about: Gartner
Jun 29, 2026, 21:00 ET Casio to Release Automatic Mechanical EDIFICE with a Look That Changes with the Light
mirror finishes accentuate the reflection of the light, presenting a unique look with every viewing angle.The dial of the EFK-200XPB and the EFK-200CD is made with the forged carbon used in high-end sports cars, highlighting the material's distinctive marbled pattern. The EFK-200XPB also features a
More news about: CASIO COMPUTER CO., LTD
Jun 29, 2026, 21:00 ET Casio to Release Automatic Mechanical EDIFICE with a Look That Changes with the Light
mirror finishes accentuate the reflection of the light, presenting a unique look with every viewing angle.The dial of the EFK-200XPB and the EFK-200CD is made with the forged carbon used in high-end sports cars, highlighting the material's distinctive marbled pattern. The EFK-200XPB also features a
More news about: CASIO COMPUTER CO., LTD
Jun 29, 2026, 21:00 ET Casio Luncurkan EDIFICE dengan Mesin Otomatis dan Tampilan yang Berubah-ubah Mengikuti Pantulan Cahaya
berbeda semakin mempertegas permainan cahaya dan menciptakan karakter visual yang unik saat dilihat dari berbagai arah.Pada EFK-200XPB dan EFK-200CD, Casio menggunakan bahan forged carbon pada bagian dial, material yang banyak digunakan pada mobil sport kelas atas. Material
More news about: CASIO COMPUTER CO., LTD
Jun 29, 2026, 21:00 ET Casio s'apprête à lancer une montre EDIFICE mécanique à remontage automatique dont l'aspect évolue en fonction de la lumière
mettent en valeur la réflexion de la lumière, offrant un aspect unique quel que soit l'angle de vue.Le cadran des modèles EFK-200XPB et EFK-200CD est fabriqué à partir de carbone forgé, un matériau utilisé dans les voitures de sport haut de gamme, ce qui souligne le motif marbré caractéristique
More news about: CASIO COMPUTER CO., LTD
Jun 29, 2026, 21:00 ET Casio trình làng mẫu đồng hồ cơ tự động EDIFICE với diện mạo thay đổi theo ánh sáng
riêng biệt giúp tăng cường hiệu ứng phản chiếu ánh sáng, mang đến một diện mạo độc đáo ở mọi góc nhìn.Mặt số của các mẫu EFK-200XPB và EFK-200CD được chế tác từ forged carbon (carbon đúc) thường được sử dụng trên các mẫu xe thể thao cao cấp, làm nổi bật họa tiết tựa vân đá cẩm thạch đặc trưng
More news about: CASIO COMPUTER CO., LTD
Jun 29, 2026, 21:00 ET 카시오, 빛에 따라 변화하는 외관의 자동 기계식 에디피스 출시 예정
블랙EFK-200CD-1A블랙
More news about: CASIO COMPUTER CO., LTD
Jun 29, 2026, 16:52 ET AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
subcutaneously. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response toward target cell types. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T-cell-mediated killing of CD20+ cells.1Epcoritamab
More news about: AbbVie
Jun 29, 2026, 16:15 ET AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
subcutaneously. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response toward target cell types. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T-cell-mediated killing of CD20+ cells.1Epcoritamab
More news about: AbbVie
Jun 29, 2026, 10:31 ET Nephrotic Syndrome Market Set for Robust Growth During the Forecast Period (2026-2036), Driven by Emerging Therapies and Expanding Research | DelveInsight
(obinutuzumab) is a humanized anti-CD20 monoclonal antibody engineered with a Type II CD20-binding domain that promotes direct B-cell elimination, along with a glycoengineered Fc region that enhances binding affinity and antibody-dependent cellular cytotoxicity (ADCC). By targeting CD20-expressing B cells, the
More news about: DelveInsight Business Research, LLP
Jun 29, 2026, 03:10 ET AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
exposure, skin papilloma was reported in adolescents in the RINVOQ 15 mg and 30 mg groups.The most commonly reported adverse reactions in the UC and CD trials (≥3% of patients) with RINVOQ 45 mg, 30 mg or 15 mg were upper respiratory tract infection, pyrexia, blood CPK increased, anemia, headache, acne,
More news about: AbbVie
Jun 29, 2026, 03:10 ET AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
exposure, skin papilloma was reported in adolescents in the RINVOQ 15 mg and 30 mg groups.The most commonly reported adverse reactions in the UC and CD trials (≥3% of patients) with RINVOQ 45 mg, 30 mg or 15 mg were upper respiratory tract infection, pyrexia, blood CPK increased, anemia, headache, acne,
More news about: AbbVie
Jun 29, 2026, 03:00 ET AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
exposure, skin papilloma was reported in adolescents in the RINVOQ 15 mg and 30 mg groups.The most commonly reported adverse reactions in the UC and CD trials (≥3% of patients) with RINVOQ 45 mg, 30 mg or 15 mg were upper respiratory tract infection, pyrexia, blood CPK increased, anemia, headache, acne,
More news about: AbbVie
Jun 29, 2026, 03:00 ET AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
exposure, skin papilloma was reported in adolescents in the RINVOQ 15 mg and 30 mg groups.The most commonly reported adverse reactions in the UC and CD trials (≥3% of patients) with RINVOQ 45 mg, 30 mg or 15 mg were upper respiratory tract infection, pyrexia, blood CPK increased, anemia, headache, acne,
More news about: AbbVie
Jun 25, 2026, 07:00 ET Roc Nation Announces JAŸ-Z 30 Celebrations Honoring 30 Years of Reasonable Doubt and the Legacy of JAŸ-Z
the soundtrack throughout the experience, creating a gathering space for fans to connect through JAŸ-Z's musicExclusive vinyl, cassette, and CD offerings celebrating Reasonable Doubt and key catalog releasesComplimentary food from Lucali's Pizza and Cloudy Donut Co. on opening
More news about: Roc Nation
Jun 24, 2026, 22:54 ET CARsgen、固形がん治療向け世界初のCAR T細胞療法製品「Satri-cel」の承認を発表
を推進することが急務となっています。Claudin18.2は、選択性の高いマーカータンパク質です。Claudin18.2の正常組織における発現は極めて限定的で、分化した胃粘膜上皮細胞でのみ認められる一方、胃がんやその他の悪性腫瘍では高発現しています。Satri-celは、Claudin18.2を標的とする自家由来CAR-T細胞製品です。この製品は、遺伝子改変により、ヒト化Claudin18.2特異的単鎖モノクローナル抗体断片（hu8E5-2I）、CD8αヒンジ領域、CD28膜貫通領域、CD28細胞内シグナル伝達ドメイン（CD28 ICD）、およびCD3ζ細胞内シグナル伝達領域から構成されるCAR構築体を発現します。当社の知る限り、固形腫瘍関連抗原であるClaudin18.2をCAR
More news about: CARsgen Therapeutics
Jun 24, 2026, 13:38 ET Children's Hospital of Philadelphia Researchers Develop Platform to Improve Adaptive Immune Responses in Cancer
recognize and fight off threats and respond to those threats faster and more effectively. A core part of this immunity requires specialized cells called CD8+ T cells, which patrol the body looking for signs of disease by reading small protein fragments displayed on cell surfaces by molecules called human
More news about: Children's Hospital of Philadelphia
Jun 24, 2026, 10:31 ET Chronic Spontaneous Urticaria Market Heats Up as Pharma Companies Race to Address Unmet Needs | DelveInsight
monoclonal antibody currently in Phase Ib/IIa development that targets the stem cell factor (SCF)/CD117 (c-Kit) signaling axis, which is critical for mast cell maintenance. By preventing the interaction between SCF and CD117, briquilimab aims to deplete mast cells in affected tissues, potentially providing therapeutic
More news about: DelveInsight Business Research, LLP
Jun 24, 2026, 08:30 ET Improve Blood Assay Analyte Preservation & Recovery with Advanced Materials, Upcoming Webinar Hosted by Xtalks
collection. Using qPCR analysis of isolated mRNA, researchers observed comparable relative expression of biomarkers associated with T cells (CD3+, CD4+, CD8+), B cells and natural killer cells between dried and liquid samples, suggesting that the fiber matrix preserves representative immune cell population
More news about: Xtalks
Jun 24, 2026, 07:30 ET ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities
an expected cash runway at least into 2028.About ZYNLONTA® ZYNLONTA® is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The
More news about: ADC Therapeutics SA